Beyond YAP1-amplified malignancies, the concurrent inhibition of YAP-TEAD and MEK-RAF pathways demonstrated synthetic lethality in tumors harboring BRAF or RAS mutations, suggesting the promise of this strategy across a wide range of cancers, particularly melanoma and non-small cell lung cancer [154,242]. This evidence concerns the gene BRAF and cancer.